randomized, waiting list–controlled clinical trial was con-ducted

delayed treatment control

statistically significant treatment condition effectswere found on self-reported depression (

significantlylower depression scores in the immediate treatment condition

Rapid and sustained antidepressant effectswere examined using t tests comparing QIDS-SR scores be-tween baseline and day 1 postsession-1 and between baselineand week 4 postsession-2 follow-up.

nxiety symptoms were mea-sured using the clinician-administered Hamilton AnxietyRating Scale

Secondary outcome measures for depressive symp-toms were the Beck Depression Inventory II

Severity of depression was assessed using the total GRID-HAMD scor

received telephone callsthat included a brief check-in and assessment for self-reported suicidal ideation or behavior and depression symp-toms

were simi-lar to procedures used in previous and ongoing studies

psi-locybin administration sessions were conducted